- Conditions
- Advanced or Metastatic Adrenocortical Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Interventions
- DS9051b
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Sarasota, Florida • New York, New York • Providence, Rhode Island
Prostate Cancer clinical trials
Directory of U.S. ClinicalTrials.gov public records for Prostate Cancer. Browse Prostate Cancer recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.
By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 10, 2026 Report an issue
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
How Prostate Cancer studies are organized in the registry
Prostate cancer studies are organized around disease-state vocabulary more than most cancers: “castration-resistant” (CRPC), “hormone-sensitive,” and “biochemical recurrence” mark distinct study populations and appear directly in listings. Active-surveillance research is typically registered as observational, so the study-type filter separates it cleanly.
These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.
Live official records
Open in full search- Conditions
- Castrate Sensitive Prostate Cancer
- Interventions
- goserelin, Enzalutamide, Abiraterone, 18F-DCFPyL, Prednisone, Radical Prostatectomy
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 99 Years · Male only
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms, Prostate Cancer Recurrent, Androgen-Insensitive Prostatic Cance, Androgen-Resistant Prostatic Cancer, Hormone Refractory Prostatic Cancer, Immunotherapy, Immune Checkpoint Inhibitor, Inhibitory Checkpoint Molecule
- Interventions
- lorigerlimab, docetaxel, Prednisone
- Biological · Drug
- Lead sponsor
- MacroGenics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 10
- States / cities
- Miami, Florida • Orlando, Florida • Boston, Massachusetts + 6 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 23
- States / cities
- Sacramento, California • Aurora, Colorado • Tampa, Florida + 19 more
- Conditions
- Opioid Consumption, Postoperative, Multimodal Analgesia, Robotic Assisted Laparoscopic Surgery, Robotic Assisted Laparoscopic Radical Prostatectomy, Prostate Cancer
- Interventions
- multimodal analgesia pathway with up-front small opioid prescription, multimodal analgesia pathway without up-front small opioid prescription, pre-implementation baseline including opioid
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 45 Years and older · Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage II Prostate Cancer AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, High-Dose Rate Brachytherapy, Multiparametric Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration
- Procedure · Radiation · Other
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Adenocarcinoma of Prostate, Radical Prostatectomy, Hepatocellular Carcinoma (HCC), Glioma, Renal Cell Carcinoma (RCC), Prostate Cancer
- Interventions
- [18F]DCFPyL, PET/MRI scanner
- Drug · Radiation
- Lead sponsor
- Ciprian Catana, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Disease
- Interventions
- Hemigland Cryoablation
- Device
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Prostate Cancer
- Interventions
- Standard of Care
- Other
- Lead sponsor
- Prostate Cancer Clinical Trials Consortium
- Other
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2032
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Tuscaloosa, Alabama • Los Angeles, California + 35 more
- Conditions
- Prostate Cancer
- Interventions
- Tivozanib, Enzalutamide
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
- Radiation · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- Houston, Texas • League City, Texas • Sugar Land, Texas
- Conditions
- Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
- Interventions
- lyophilized black raspberry confection, laboratory biomarker analysis, dietary intervention, quality-of-life assessment, questionnaire administration
- Drug · Other · Dietary Supplement + 1 more
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
About this Prostate Cancer clinical trials directory page
- What this page lists
- U.S. ClinicalTrials.gov public records that list Prostate Cancer as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Prostate Cancer.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.
Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Prostate Cancer.